Researchers and scientists seem to be working non-stop these days in the race to end Alzheimer’s disease. Recently, the National Institutes of Health announced that the experimental drug BPN14770
is poised to begin a clinical human trial, which means, if all goes well, a new Alzheimer’s treatment could be on the market soon. With less potential side effects than its precursor, rolipram
, BPN14770 shows promising results in enhancing memory and cognitive performance in mice impacted by Alzheimer’s.
The first phase of the study will involve testing the safety of the drug in 48 healthy human volunteers, and based on those results, will then move into testing its effects on cognitive functioning, memory and learning abilities.
Unlike other studies currently underway focused on targeting amyloid plaques, BPN14770’s intended outcome is to enhance the biochemical pathway in the brain that’s responsible for formation of nerve synapses and memory. Ideally, the use of BPN14770 can eventually also aid in treating other neurological conditions
, such as schizophrenia, Fragile X syndrome, and developmental disabilities.
At Cascade Companion Care, we are always keeping our finger on the pulse of the latest Alzheimer’s and dementia care news. We’ll continue to keep you updated on the progression of these exciting new developments in the quest to overcome the challenges of Alzheimer’s!
Need help caring for a loved one with Alzheimer’s or dementia? Click here
to learn more about our Alzheimer’s and dementia care services in Northwest Washington or contact our care experts
today to find out how we can help your family.